Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
external link icon
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% Raises revenue guidance to $655-$665 million for full year 2021 Completes acquisition of affinity ligands innovator Avitide Inc.
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2021. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2021, updates to our financial guidance for the fiscal year 2021 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We delivered strong overall performance during the third quarter, with record revenue of $178 million and organic growth of 77% year-over-year. Our base business delivered 49% organic growth, reflecting an
external link icon
Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69%
Growth driven by combination of COVID-related demand, base business strength and acquisition revenue WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) -   Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2021, and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I am extremely proud of the way our team executed here in the first quarter.  With unprecedented demand driven by strong COVID tailwinds, our whole team pivoted to deliver an impressive quarter with 88% growth and 69% organic. COVID revenue contribution ticked up to 25%
external link icon
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $94.1 million with strong margin expansion
Overall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $ 348 -$ 352 million and overall revenue growth to 29%-30% for full year 2020, representing 23 %- 24 % organic growth Completes acquisition of Non-Metallic Solutions and an nounces a greement to a cquire b ioprocess s ystems i nnovator ARTeSYN Biosolutions WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2020. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our momentum
external link icon
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year
Raises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2019. Provided in this press release are financial highlights for the three- and nine-month periods ended September 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our strong performance in the third quarter, reporting over $69 million in revenue and robust organic growth of 28%. Our filtration and chromatography franchises continued to track ahead of expectations and in process analytics, our C
external link icon
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growth Raises revenue guidance to $235-$241 million for full year 2019, representing 22%-25% organic growth  Enters agreement to acquire analytics leader C Technologies Closes follow-on offering for net proceeds of $190 million WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2019. Provided in this press release are financial highlights for the three-month period ended March 31, 2019, recent business highlights, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m extremely pleased with our accomplishments and performance during the first quarter. We executed on our business and
external link icon
Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program
Repligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Under the terms of the agreement, Repligen is entitled to receive up to $70 million from Pfizer, commencing with an upfront payment of $5 million and total potential future milestone payments of up to $65 million as well as royalties on any future sales of SMA compounds developed under the agreement. SMA is an orphan neurodegenerative genetic disease that presents early in life. “This agreement is consistent with the strategic decision we announced in August 2012 to focus Repligen’s internal efforts on the growth of our bioprocessing business, while seeking external partners for our
external link icon
Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
external link icon
Repligen Acquires Business of Novozymes Biopharma Sweden AB Creates World-Leading Supplier of Products for Manufacturing Biologic Drugs Accelerates Path to Near-Term, Sustainable Profitability
external link icon
Repligen Added to the Russell 2000 Index
Repligen Corporation (NASDAQ:RGEN) today announced that the Company’s stock has been added to the Russell 2000 ® index, a subset of the Russell 3000 ® and the Russell Global ® indexes. Russell Investments’ annual index reconstitution was finalized on June 22, 2012. The Russell indexes are widely used by investment managers and institutional investors as proxies for asset allocation and as performance benchmarks for investment strategies. “We are pleased that Repligen has been added to the Russell 2000 index, and believe that our inclusion will enhance our visibility among institutions that rely on equity indexes as part of their investment strategy,” stated Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 is a subset of the Russell 3000 Index and is constructed to provide a comprehensive and unbiased small-cap barometer. It is reconstituted
external link icon
Repligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017
WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2016 financial results on Wednesday, February 22, 2017. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2016. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 73917985. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 73917985.